BVN reports Q1 2026 results on April 30 with short sellers in retreat and options positioning elevated — a split setup heading into a print where the last quarterly reaction cost holders nearly 8%.
The most notable shift in positioning is the sharp unwinding of short interest over the past month. Estimated short shares have fallen 20% since late March, dropping from roughly 5.7 million to just under 3.9 million. The pace of covering accelerated through April, with another 7% reduction over the past week alone. At 2.75% of free float, the short base is modest but not negligible — and the direction of travel is clearly toward the exits ahead of the announcement. The borrow market reinforces this: cost to borrow has slipped back to under 0.5% after a brief spike to nearly 2% on April 22, and availability is exceptionally loose at effectively the ceiling of the measurement range. There is no squeeze dynamic here — shorts who want out face no friction.
Options tell a different story. Put/call ratio is running at 1.43, broadly in line with its 20-day average of 1.42 and far above the 52-week low of 0.07. That elevated baseline reflects a structurally cautious options market for BVN — investors have maintained heavier put coverage for weeks, even as the PCR eased slightly from its April 21 peak of 2.15. The setup suggests protective positioning rather than aggressive new bearish bets. Combined with the short-covering trend, the picture is one of hedgers staying hedged while directional shorts reduce exposure.
The Street is cautious but not bearish. Scotiabank, the most active coverage name, raised its target to $44 in early March — a meaningful lift from the $27 range it had been operating in through late 2025 — while keeping a Sector Perform rating. That $44 target sits well above the current price of $30.02, implying the analyst sees recovery runway but is unwilling to push the conviction call. The mean analyst target of $40.08 aligns with that view. Valuation multiples are compressing alongside the price: the P/E has drifted down to 7.8x and the P/B to 1.5x, both softer over the past month, while EV/EBITDA holds near 7.2x. The factor scorecard highlights one standout — BVN ranks in the 89th percentile on EPS surprise history, suggesting the company has a track record of beating estimates. But 90-day EPS momentum scores just 72 and 30-day momentum has weakened to the 20th percentile, flagging that forward estimates have softened into the print.
Ownership is concentrated among long-term insiders and strategic holders. The E. Abaroa Foundation holds nearly 19% of shares, and several members of the Benavides and Dasso families together account for another 16%-plus — a structure that limits the free float and keeps governance tightly held. Among institutional names, Mirae Asset and Boston Partners both added meaningfully in Q1 2026, with Mirae adding nearly 800,000 shares. Fidelity International was also a buyer in the prior quarter. Westwood Global trimmed by roughly 500,000 shares in Q4 2025, the only notable institutional reduction in recent filings.
The earnings history sharpens the stakes. The most recent comparable print, in late February 2026, produced a 9% one-day jump — followed by a nearly 7% reversal over the subsequent five days. The prior quarter's result landed with a 4% gain on the day before also giving back most of the move over the following week. Sector peers had a rough week in parallel: AEM fell 6.8% on the week, AU dropped 6.5%, and NEM was the lone relative outperformer among the large caps, roughly flat over seven days. BVN's own 5.7% weekly decline puts it broadly in line with the group selloff rather than showing idiosyncratic pressure.
The focus on April 30 will be whether Q1 production numbers and cost guidance on the San Gabriel project support the sharp re-rating in analyst targets since the start of the year — or whether the 30% target lift from Scotiabank proves premature.
See the live data behind this article on ORTEX.
Open BVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
